The World Health Organization hopes to encourage the development of novel therapies for tuberculosis by spotlighting key clinical study characteristics.
The agency’s effort to fight the deadly disease now includes taps the pharma company’s testing tools to help speed up diagnosis and grow treatment access.
Drug industry efforts to develop a Zika vaccine are accelerating but it will be at least 18 months until the first candidates are ready for trials according to the WHO.
Vaccine developer Aeras and CMO (contract manufacturing organization) IDT Biologika have formed a strategic partnership that includes the acquisition of Aeras's Biopharmaceutical Development Center (BDC) manufacturing facility by IDT.
The WHO has yet to decide how to investigate if barriers to competition are preventing vaccine price cuts after World Health Assembly members committed to probe the jabs industry.
Janssen-Cilag’s bedaquiline and Otsuka’s delamanid notwithstanding, the drug industry is not spending enough on the development of tuberculosis medicines according to the WHO.
SRI International was awarded a seven-year, $49m contract from the NIAID (National Institute of Allergy and Infectious Diseases), which is a division of the NIH (National Institutes of Health), for preclinical HIV/AIDS work.
The WHO, the United States Pharmacopeial Convention (USP) and the US Agency for International Development (USAID) will work with regulators to help countries manufacture a key tuberculosis drug.
The US drought of the TB treatment isoniazid may soon ease after some manufacturers on the US FDA drug shortage list resume supply, but rationing looks set to continue for now.
Ongoing shortages of the API isoniazid are forcing US state health departments to ration TB (tuberculosis) drugs and - for some patients - forego treatment altogether, a Johns Hopkins University expert told us.
The Chao Center for Industrial Pharmacy and contract manufacturing is to donate $360,000 worth of the antibiotic Seromycin to the Global Health Committee’s fight against multidrug rtesistant tuberculosis (MDR-TB) in Cambodia and Ethiopia.
According to the international medical humanitarian organisation
Médecins Sans Frontières (MSF), the World Health Organisation (WHO)
has failed to address the emergence of extensively drug-resistant
(XDR) tuberculosis.
The World Health Organisation (WHO) has revealed details of a
'super strain' of tuberculosis, which is not only resistant to
first choice treatment drugs, but also three or more of the six
classes of second-line drugs.
Omnia Biologics has sealed a deal to help the Aeras Global TB
Vaccine Foundation in its quest to make quantities of a new TB
Vaccine that will "fulfil all the needs of the developing
world."
A new study has revealed the existence of new drug targets for
tuberculosis (TB) treatments, which could essentially dictate the
design of TB drugs of the future. The bacterium that causes TB
currently infects one person in three...
An experimental TB drug has proved effective against multi
drug-resistant forms of the disease as well as becoming the first
compound to treat the latent stage of this disease, which affects
nearly a third of the world's population,...
Oxford Immunotec makes available an in vitro diagnostic that
measures T-cells specific to Mycobacterium tuberculosis (MTB)
antigens diagnosing both latent and active TB infection in
immunocompromised humans - a significant problem...
Norwegian biotechnology firm, Genpoint, is running trials of new
DNA tests for tuberculosis (TB) in which its novel DNA method aims
to cut diagnosis time, cheaper and quicker without an increase of
personnel in the health care sector.
The Foundation for Innovative New Diagnostics (FIND) and Eiken
Chemicals have announced a collaboration to develop a rapid and
simple test for the detection of active tuberculosis (TB), a
disease that has infected close to a third...
A new laboratory application for detecting tuberculosis, which cuts
waiting time from 24 hours to three minutes using a technique that
identifies TB antigens, has been made available by Proteome
Systems. The application is set to...
The Global Alliance for TB Drug Development has started testing a
promising tuberculosis drug in humans. This development represents
the first novel compound of a new class to be introduced for the
treatment of TB in more than 40...
A tuberculosis drug candidate, which has been described as the most
promising Tuberculosis (TB) drug in 40 years, may lead to a shorter
and more effective treatment.
Researchers have uncovered a novel treatment that could prove to be
effective against tuberculosis (TB), a disease that has made a
comeback due to the emergence of resistant strains of the offending
bacterium and the spread of AIDS.
A class of drug, which is currently used to fight respiratory tract
infections, has demonstrated pharmacological features and potential
antibacterial drug activity that may prove effective against
Tuberculosis, which is currently...
A novel approach to treating tuberculosis (TB), focusing on a
potential drug target in the cell walls of Mycobacterium
tuberculosis, the bacterium that causes TB, a disease that is
reappearing as new, multiresistant drug-strains.
Researchers in the UK are developing an oral tuberculosis vaccine
for badgers based on alginate gel beads, which protect the bacteria
from stomach acid until it reaches the intestine. They say the
technology could also work for human...
The European Commission has announced a collaborative tuberculosis
research initiative, underpinned by €32 million in funding for two
overlapping research projects aimed at developing an improved
vaccine for the disease. The news...
